Loading...
Docoh

Viveve Medical (VIVE)

Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in more than 50 countries.

Company profile

VIVE stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
13 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 9.43M 9.43M 9.43M 9.43M 9.43M 9.43M
Cash burn (monthly) 1.54M 1.33M 1.67M 1.83M 1.52M 1.3M
Cash used (since last report) 2.24M 1.94M 2.44M 2.67M 2.22M 1.89M
Cash remaining 7.19M 7.49M 6.99M 6.76M 7.21M 7.54M
Runway (months of cash) 4.7 5.6 4.2 3.7 4.7 5.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
4 Jan 22 Scott Durbin Incentive Stock Option (Right to Purchase) Common Stock Grant Acquire A No No 1.26 258,000 325.08K 258,000
4 Jan 22 Basta Steven L NQSO Common Stock Grant Acquire A No No 1.26 48,000 60.48K 48,000
4 Jan 22 Debora Jorn NQSO Common Stock Grant Acquire A No No 1.26 22,000 27.72K 22,000
4 Jan 22 Morris Arlene NQSO Common Stock Grant Acquire A No No 1.26 22,000 27.72K 22,000
4 Jan 22 Sharon Collins Presnell NQSO Common Stock Grant Acquire A No No 1.26 18,000 22.68K 18,000
3.0% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 19 22 -13.6%
Opened positions 4 6 -33.3%
Closed positions 7 2 +250.0%
Increased positions 3 6 -50.0%
Reduced positions 5 4 +25.0%
13F shares Current Prev Q Change
Total value 2.89M 4.56M -36.5%
Total shares 1.33M 2.75M -51.7%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Lincoln Park Capital Fund 701K $2.23M 0.0%
BLK Blackrock 244.23K $259K +0.0%
Vanguard 114.01K $121K -19.2%
Renaissance Technologies 59.45K $63K +3.0%
STT State Street 55.37K $59K +1.2%
Geode Capital Management 51.36K $54K 0.0%
Two Sigma Advisers 22.3K $24K -8.2%
Millennium Management 19.6K $21K -31.7%
NTRS Northern Trust 17.07K $18K 0.0%
Ergoteles 16.6K $18K NEW
Largest transactions Shares Bought/sold Change
Empery Asset Management 0 -1.03M EXIT
Hudson Bay Capital Management 0 -258.06K EXIT
VIRT Virtu Financial 0 -35.03K EXIT
Dimensional Fund Advisors 0 -30.62K EXIT
Citadel Advisors 0 -27.9K EXIT
Vanguard 114.01K -27.1K -19.2%
MS Morgan Stanley 17 -22.57K -99.9%
Ergoteles 16.6K +16.6K NEW
Quadrant Private Wealth Management 10K +10K NEW
Millennium Management 19.6K -9.11K -31.7%

Financial report summary

?
Competition
HologicCuteraInmode

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: bid, bulletin, calendar, consecutive, decline, delisted, delisting, Department, distressed, electronic, laying, led, listed, listing, media, notice, OTC, Pink, regain, shortly, sixteenth, track, unlisted, upcoming, written
Removed: ASC, FASB, relied